
    
      Tarceva administered on continuous oral dosing schedule at 150 mg/day for pts not on EIAEDs &
      450 mg/day for pts on EIAEDs. Starting dose level of dasatinib will be 100 mg once day via
      continuous oral daily dosing. Dasatinib will be increased in successive cohorts of enrolled
      pts. Pts will remain on treatment until excessive toxicity, progressive disease, withdrawal
      of consent/death.

      Pts have confirmed diagnosis of recurrent/progressive WHO gr IV MG / WHO grade III MG. Phase
      I 3+3 dose escalation design w 2 independently escalated stratum: stratum A-pts not on
      CYP3A-enzyme inducing anti-epileptic drugs; stratum B-pts on EIAEDs. Assessment of safety
      will be based mainly on frequency of adverse events, particularly adverse events leading to
      discontinuation of treatment & on number of significant lab abnormalities.
    
  